...
机译:在Vismodegib停止后,在局部晚期基础细胞癌的多焦点复发中未选择Vismodegib抗突变
Institute of Skin Research INSERM U 976Saint Louis HospitalParis France;
Institute of Skin Research INSERM U 976Saint Louis HospitalParis France;
Cambridge Institute for Medical ResearchUniversity of CambridgeCambridge UK;
Institute of Skin Research INSERM U 976Saint Louis HospitalParis France;
Institute of Skin Research INSERM U 976Saint Louis HospitalParis France;
Institute of Skin Research INSERM U 976Saint Louis HospitalParis France;
Department of Dermatology AP‐HPH?pital Saint‐LouisParis France;
Institut RocheBoulogne‐Billancourt France;
Institut RocheBoulogne‐Billancourt France;
Institute of Skin Research INSERM U 976Saint Louis HospitalParis France;
Institute of Skin Research INSERM U 976Saint Louis HospitalParis France;
机译:在Vismodegib停止后,在局部晚期基础细胞癌的多焦点复发中未选择Vismodegib抗突变
机译:在Vismodegib撤离和重新诱导临床患者的患者患者中,在临时先进的基础细胞癌的患者中重新诱导完全反应
机译:在局部晚期基底细胞癌的治疗中由于平滑化突变而获得的对Hedgehog途径抑制剂vismodegib的耐药性
机译:IL-12是一种有用的标记,可预测放疗中的临床结果:IL-12的下调增加了局部晚期肝细胞癌的治疗失败
机译:TGFbeta耐药人类癌细胞系中的新型显性负Smad2突变。
机译:Vismodegib在Neoadjuvant治疗当地先进的基础细胞癌:多中心开放标签第2阶段试验(Vismoneo研究):Neoadjuvant Vismodegib在当地先进的基础细胞癌
机译:vismodegib和辅助放疗的同情使用可治疗多种局部晚期和不可手术的皮肤基底细胞癌和鳞状细胞癌